Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Convocatoria de la Junta General de Accionistas de 2026
Regulatory Filings
2026-05-06 Spanish
Convocatoria de la Junta General de Accionistas de 2026
Regulatory Filings
2026-05-06 Spanish
Informe de negocio del primer trimestre de 2026
Regulatory Filings
2026-04-30 Spanish
Faes Farma anuncia la celebración de un webcast para presentar los resultados del primer trimestre de 2026
Regulatory Filings Classification · 75% confidence The document is a brief notice filed with the Spanish CNMV under “Otra Información Relevante” announcing a webcast date/time for Q1 2026 results. It does not contain the actual earnings figures or Q&A transcript, nor is it a full financial report, dividend notice, management change, or any other specific category. It is a general regulatory announcement of an upcoming event, so it falls into the fallback Regulatory Filings category (RNS).
2026-04-22 Spanish
Informe de negocio 2025
Investor Presentation Classification · 98% confidence The document is a comprehensive 'Informe 2025' (2025 Report) for Faes Farma. It contains detailed financial results, business unit performance, sustainability strategies, and management commentary on the fiscal year 2025. Given its length (over 25,000 characters), detailed financial tables, and strategic outlook, it functions as an annual performance report. While it is not a formal 10-K (which is a specific US regulatory filing), it serves the same purpose as an Annual Report for a non-US entity, providing a full review of the company's yearly activity and financial performance.
2026-02-26 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2025
Remuneration Information Classification · 100% confidence The document is a detailed report on the remuneration policy for directors of Faes Farma, S.A. It covers the procedures for determining compensation, the mix of fixed and variable pay, long-term incentive structures, and clawback/malus clauses. This content is characteristic of a Remuneration Report, which is a standard component of proxy statements or standalone governance filings. Given the specific focus on executive and director compensation policies, it falls under the 'DEF 14A' category.
2026-02-26 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.